Sundial: Analysts Expect Positive EBITDA For Q3 2021

Sundial Growers (NASDAQ: SNDL) announced that they will be reporting their third quarter financials after the markets close on November 10th.

Analysts have a consensus US$0.71 12-month price target on the company, via a total of 5 analysts, with 4 analysts having hold ratings, and one other analyst has a sell rating on the company. The street high comes from ATB Capital Markets with a US$0.80 price target, and the lowest target comes from Cantor Fitzgerald with a US$0.00 price target.

Only 4 analysts have revenue estimates for the third quarter. The mean between all 4 is C$16.48 million; this number has been remained flat since the start of May. The street high is C$19.1 million while the lowest sits at C$11.40 million.

Only two analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 35.3%, with this number being flat at the start of May. Street high is a 40.6% estimate and the lowest sits at 30%.

Onto EBITDA estimates, there are currently only 3 analysts who have third-quarter EBITDA estimates. The mean is currently C$0.97 million, with this number being slightly higher than at the start of May. Street high sits at C$2 million EBITDA and the lowest being a (C$0.4) million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

First Majestic Q1 Earnings: A Bang Up Quarter

Copper’s Structural Shortage May Be Here to Stay | Colin Joudrie – Selkirk Copper

Why Barrick’s “Strong” Quarter Wasn’t So Strong | Q1 2026 Earnings

Recommended

Questcorp Wraps Expanded Drone Survey at La Union as Summer Drilling Approaches

Altamira Gold Extends Maria Bonita Footprint with 110 Metre Step-Out

Related News

Ayr Wellness Sees Canaccord Cut Target To $30 Following Q2 Miss

On August 18, Ayr Wellness (CSE: AYR.A)s reported its second quarter financial results. The company...

Sunday, September 4, 2022, 03:01:00 PM

Antibe Therapeutics: Canaccord Initiates Coverage, Issues $1.50 Price Target

Recently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company...

Tuesday, August 18, 2020, 01:46:28 PM

Organigram: Canaccord Reiterates $3.50 Target

On July 13th, Organigram Holdings (TSX: OGI) (NASDAQ: OGI) reported their fiscal third-quarter results. The...

Monday, July 19, 2021, 02:13:00 PM

Electronic Arts: Fourth Quarter Consensus Estimates

Electronic Arts (NASDAQ: EA) will be reporting their fiscal fourth quarter financial results this evening...

Tuesday, May 11, 2021, 03:23:00 PM

Canadian Cannabis: Canaccord Lifts Cronos Target, Reiterates Canopy Growth And Tilray Ratings

Yesterday Canaccord Genuity Capital Markets put out a second-quarter preview note on the top Canadian...

Thursday, July 28, 2022, 03:02:00 PM